Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025
The accuracy of Fibrosis score from FibroScan in diverse pediatric liver diseases at a single tertiary center.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jarasvaraparn Chaowapong, Anderson Brendan P, Tolliver Kyla, Adams Kathryn H, Bozic Molly, Molleston Jean P
Аннотация
BACKGROUND: Liver biopsy is the gold standard for fibrosis evaluation. We investigated the correlation of biomarkers such as AST-to-platelet ratio index (APRI), Fibrosis-4 (FIB-4), and liver stiffness measurement (LSM) from FibroScan with severity of fibrosis on liver biopsy in children with liver disease.
METHODS: We performed a retrospective analysis of children who underwent FibroScan. Advanced liver disease (aLD) was defined as fibrosis score 3-4 on liver biopsy.
RESULTS: A total of 1004 children were included in this analysis. The two most common diagnoses were metabolic associated steatotic liver disease (MASLD) 658 (65.5 %) with liver biopsies in 136 (20.6 %), and liver transplant (LT) 74 (7.4 %) with liver biopsies in 45 (60.8 %). The APRI, FIB-4, and LSM were significantly correlated with fibrosis scores (Pearson correlation 0.25, p = 0.006, 0.19, p = 0.04, 0.50, p < 0.001, respectively) in MASLD. In LT, or autoimmune hepatitis (AIH), only LSM had significant correlation with fibrosis score. LSM greater than 8.5 kPa predicted aLD in MASLD, LT, and AIH. LSM, APRI, and FIB-4 did not change significantly during the approximate annual follow-up.
CONCLUSIONS: LSM correlates better with aLD than APRI and FIB-4 on liver biopsy in children with MASLD, LT, and AIH. FibroScan can be useful to screen for aLD in children with liver disease.
METHODS: We performed a retrospective analysis of children who underwent FibroScan. Advanced liver disease (aLD) was defined as fibrosis score 3-4 on liver biopsy.
RESULTS: A total of 1004 children were included in this analysis. The two most common diagnoses were metabolic associated steatotic liver disease (MASLD) 658 (65.5 %) with liver biopsies in 136 (20.6 %), and liver transplant (LT) 74 (7.4 %) with liver biopsies in 45 (60.8 %). The APRI, FIB-4, and LSM were significantly correlated with fibrosis scores (Pearson correlation 0.25, p = 0.006, 0.19, p = 0.04, 0.50, p < 0.001, respectively) in MASLD. In LT, or autoimmune hepatitis (AIH), only LSM had significant correlation with fibrosis score. LSM greater than 8.5 kPa predicted aLD in MASLD, LT, and AIH. LSM, APRI, and FIB-4 did not change significantly during the approximate annual follow-up.
CONCLUSIONS: LSM correlates better with aLD than APRI and FIB-4 on liver biopsy in children with MASLD, LT, and AIH. FibroScan can be useful to screen for aLD in children with liver disease.